Steven R. Patierno, Ph.D.
Deputy Director, Duke Cancer Institute
Professor of Medicine
Professor of Pharmacology and Cancer Biology
Professor of Community and Family Medicine
As Deputy Director of the Duke Cancer Institute (DCI), Dr. Patierno helps lead a top-ranked NCI-designated Comprehensive Cancer Center dedicated to delivering leading-edge, compassionate, multi-disciplinary care from screening to survivorship, advancing trans-disciplinary research and providing authentic community engagement for health education, prevention and access to care. One of the original eight NCI-designated Comprehensive Cancer Centers, DCI is one of only 46 such Centers in the US, with more than 75,000 unique annual patient visits, over 7500 new cancer diagnoses annually, and >2500 annual enrollments in clinical trials. The DCI includes more than 300 investigators with more than $150 million in annual cancer research funding.
Joining the Duke University Medical Center in 2012, Dr. Patierno serves as a Professor of Medicine, Professor of Pharmacology and Cancer Biology, and Professor of Community and Family Medicine. He has broad responsibility across the continuum of cancer care and cancer research: basic, translational, clinical, and population, and is the senior scientific and operational leader for cancer control and population sciences, cancer supportive care and survivorship services and research, patient experience research, cancer care quality and implementation science, cancer health equity and disparities, global cancer, cancer and the environment, and cancer outcomes, economics and policy. Prior to joining Duke, Dr. Patierno served as Executive Director of The George Washington University Cancer Center, and the Vivian Gill Distinguished Professor of Oncology at the GWU School of Medicine and Health Sciences. His prior training includes a B.S. in Pharmacy from the University of Connecticut, a PhD in molecular pharmacology from the Graduate School of Biomedical Science, University of Texas Health Science Center-MD Anderson Cancer Institute in Houston Texas, and an NIH-funded postdoctoral fellowship at the University of Southern California (USC) Norris Comprehensive Cancer Center in molecular oncology and carcinogenesis.
Dr. Patierno’s basic science and translational research laboratory has been funded continuously by the NIH, NCI and/or Department of Defense for nearly 25 years. He is internationally recognized for his research on molecular carcinogenesis, molecular pharmacology, and healthcare delivery research on patient navigation. For the past 10 years his laboratory has been focused NCI-, DOD- and PCF-funded research on the genomics and molecular biology of cancer disparities including the development of biomarkers for high risk prostate cancer, identification of novel molecular therapeutic targets, and development of innovative approaches to molecularly targeted therapeutics. He has also led a number of large, multi-institutional, patient-centered, community-based and healthcare delivery grants from the NCI, CDC, numerous foundations, industry, and state-wide consortiums addressing cancer disparities, prevention, control, education, outreach, survivorship. He is nationally recognized in cancer healthcare delivery and policy, and has received numerous awards for his local, state and national leadership in health disparities. He is also experienced in biomedical entrepreneurship, with 14 U.S. patents and several biotechnology and healthcare delivery companies that he co-founded and/or serves as an advisor to. Dr. Patierno is a distinguished educator, having successfully trained more than 50 graduate students and fellows, as well as led NIH-, NCI- and ACS-funded training programs in basic and translational biomedical sciences. He is currently Co-Principle Investigator to an NIEHS-funded training grant in environmental health sciences and an NCI-funded P20 PACHE grant to support the North Carolina Central University-Duke Cancer Institute Translation Cancer Disparities Research Partnership, which trains minority graduate students, postdoctoral fellows and early-stage investigators in translational cancer disparities research.